Evidence map›Paper›PMID 42764335›Full record

ArticleNature communications2026

A unified and desymmetric approach to axially chiral atropisomers.

Dan Hu, Yu Huang, Wenxuan Lin, Tao Zhang, Penghui Li, Zihao Jiao, Linghui Qian, Yu Lan, Xin Li, Jia-Yu Liao

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dan Hu *National Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, and Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou, 310058, China.
Yu Huang *National Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, and Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou, 310058, China.
Wenxuan LinSchool of Chemistry and Chemical Engineering, Chongqing Key Laboratory of Chemical Theory and Mechanism, Chongqing University, Chongqing, 401331, China. 06723625@alu.cqu.edu.cn.ORCID http://orcid.org/0009-0004-2587-0130
Tao ZhangInstitute of Intelligent Innovation, Henan Academy of Sciences, Zhengzhou, 451162, China.ORCID http://orcid.org/0009-0009-8039-5738
Penghui LiInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, 518132, China.
Zihao JiaoInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, 518132, China.
Linghui QianNational Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, and Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou, 310058, China.ORCID http://orcid.org/0000-0001-7889-1489
Yu LanSchool of Chemistry and Chemical Engineering, Chongqing Key Laboratory of Chemical Theory and Mechanism, Chongqing University, Chongqing, 401331, China.ORCID http://orcid.org/0000-0002-2328-0020
Xin LiInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, 518132, China. lixin@szbl.ac.cn.ORCID http://orcid.org/0000-0001-9698-1883
Jia-Yu LiaoNational Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, and Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou, 310058, China. jyliao@hkbu.edu.hk.ORCID http://orcid.org/0000-0001-6847-4825

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22303099National Natural Science Foundation of China (National Science Foundation of China) 22501247National Natural Science Foundation of China (National Science Foundation of China) 22577080National Natural Science Foundation of China (National Science Foundation of China) 82273887Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) 2614050002196Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LTZ22B020001Shenzhen Science and Technology Innovation Commission QNXMB20250701094331043
6 · The paper itself

Abstract

Given the widespread applications of axially chiral atropisomers, the development of catalytic asymmetric transformations toward their preparation has been an important goal in organic synthesis and is under intensive investigation. However, the majority of precedented methods focused on only one specific type of chiral X-Y axis, while the implementation of a unified approach that is capable of accessing diverse types of stereogenic X-Y axes has largely lagged, remaining an unmet synthetic challenge. Herein, we report a modular platform for constructing axially chiral atropisomers, for which four structurally distinct types of frameworks bearing either a C-C, C-N, N-N, or C-O axis are generated in high yields with high enantioselectivities. The success of this study lies in the development of an efficient silver-catalyzed desymmetric Schöllkopf reaction of prochiral dicarboxylic esters with isocyanoacetates. Mechanistic studies indicate that for the C-C, C-N, and C-O atropisomers, the origin of enantioselectivity comes solely from the desymmetrization process, while for the N-N atropisomers the subsequent kinetic resolution contributes synergistically. Density functional theory (DFT) calculations further elucidate that this stereocontrol is dictated by ligand-substrate steric repulsion during the rate-determining nucleophilic addition step.

Identifiers

PMID42764335
PMCPMC13590545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.